Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Sorafenib is a drug being studied for the treatment of cancer. Sorafenib has been shown to
block certain proteins on the surface of some cancer cells called "growth factor receptors."
Blocking these growth factor receptors can slow or stop cancer cell growth.
Sorafenib is also known as Nexavar®. It has been studied in other types of cancers, including
kidney cancer, and has been approved by the Food and Drug Administration (FDA) for treating
advanced kidney cancer. Because it is not approved by the FDA for treating esophageal cancer,
it is considered an experimental treatment.
The purpose of this study is to determine what effects sorafenib has on advanced esophageal
cancer. These effects include whether sorafenib can shrink the tumor or slow down its growth
and what side effects sorafenib will have on the tumor.